Glucose Injection BP Minijet 50%w/v, Solution for injection

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Anhydrous glucose

Available from:

International Medication Systems (UK) Ltd

ATC code:

V06DC; V06DC01

INN (International Name):

Anhydrous glucose

Dosage:

50 percent weight/volume

Pharmaceutical form:

Solution for injection

Prescription type:

Product subject to prescription which may not be renewed (A)

Therapeutic area:

Carbohydrates; glucose

Authorization status:

Not marketed

Authorization date:

1977-09-08

Patient Information leaflet

GLUCOSE INJECTION MINIJET
®
50% W/V SOLUTION FOR INJECTION
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS
MEDICINE.
• Keep this leaflet. You may need to read it again
• If you have any further questions, ask your doctor or
nurse
• This medicine has been prescribed for you. Do not pass it
on to others. It may harm them, even if their symptoms
are the same as yours
• In this leaflet, Glucose Injection Minijet, 50 % w/v will be
called Glucose Injection.
IN
THIS LEAFLET:
1. What Glucose Injection is for
2. Before you are given Glucose Injection
3. How Glucose Injection will be given to you
4. Possible side effects
5. How to store Glucose Injection
6. Further information.
1. WHAT GLUCOSE INJECTION IS FOR
Glucose is a naturally occurring sugar.
A glucose injection may be used for the following reasons:
• As a source of energy for the body. (e.g. as intravenous
feeding)
• When the blood sugar level is dangerously low
• To reduce pressure inside the head caused by alcohol
intoxication or withdrawal effects from alcohol (the
‘DTs’)
As Glucose Injection is only used in medical e
mergencies, the
injection will be given by a doctor or nurse in a hospital.
2. BEFORE YOU ARE GIVEN GLUCOSE INJECTION
DO NOT USE GLUCOSE INJECTION IF:
• You are allergic to glucose
• You are allergic to corn or corn products
• You have had a stroke
• You are in a diabetic coma (hyperglycaemic coma) as a
result of too much sugar
• You are unable to urinate
• You have bleeding in the brain or spine (e.g. from a stroke
or aneurysm)
• You have withdrawal effects from alcohol (the ‘DTs’) but
ar
e already dehydrated
• You are a child under 6 years.
If any of the above applies to you talk to your doctor or nurse.
CHECK WITH YOUR DOCTOR BEFORE YOU ARE GIVEN GLUCOSE
INJECTION IF:
• You are allergic to carbohydrates
• You have asthma
• You have diabetes
• You are very undernourished
• You have thiamine (vitamin B) deficiency
• You have been told that you have low phosphate levels in
your blood

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Glucose Injection BP Minijet 50%w/v, Solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Glucose anhydrous 500 mg in 1ml as 5g/10 ml and 25g/50 ml
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection
The clear, colourless solution, is contained in a type 1 glass vial
with an elastomeric closure. The container is specially
designed for use with the IMS Minijet injector supplied.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
a)
As a source of energy in parenteral nutrition.
b)
In severe hypoglycaemia due to insulin excess or other causes.
c)
For the treatment of_ delirium tremens_ or acute alcohol intoxication.
Glucose injection 50% w/v is strongly hypertonic and is used partly
because of its dehydrating effects. In delirium
tremens or acute alcohol intoxication the patient must be rehydrated.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Hypertonic solutions of glucose should be administered via a central
vein. The dose is variable and depends upon the
indication, clinical condition and size of the individual.
The rate of utilisation of glucose varies considerably from patient to
patient. In general, the maximal rate has been
estimated at 500-800mg/kg body weight/hour. If the patient's capacity
to utilise glucose is exceeded, glycosuria and
diuresis will occur.
Use as a calorie source in Total Parenteral Nutrition (TPN)
Fluid balance, serum glucose, serum sodium and other electrolytes may
need to be monitored before and during
administration, especially in patients with increased non-osmotic
vasopressin release (syndrome of inappropriate
antidiuretic hormone secretion, SIADH) and in patients co-medicated
with vasopressin agonist drugs due to the risk of
hyponatraemia.
Monitoring of serum sodium is particularly important for
physiologically hypotonic fluids. Glucose containing
solutions may become extremely hypotonic after administration due to
glucose metabolization in the body (see sections
4.